Instruction for use: Tamoxifen HEXAL

Active substance Tamoxifen

ATX code L02BA01 Tamoxifen

Pharmacological groups

Estrogens, gestagens; Their homologues and antagonists

Antineoplastic hormonal agents and hormone antagonists

Nosological classification (ICD-10)

C50 Malignant neoplasm of breast

Cancer of the nipple and areola of the breast, Breast carcinoma, The hormone-dependent form of recurrent breast cancer in women in menopause, Hormone-dependent breast cancer, Disseminated breast carcinoma, Disseminated Breast Cancer, Malignant breast cancer, Malignant neoplasm of breast, Contralateral breast cancer, Locally advanced or metastatic breast cancer,Locally-distributed breast cancer, Locally-recurring breast cancer, Metastatic breast carcinoma, Metastasis of breast tumors, Metastatic breast carcinoma, Inoperable breast carcinoma, Incompatible breast cancer, Breast cancer in women with metastases, Breast cancer in men with metastases, Breast Cancer, Breast cancer in men, Mammary cancer, Breast cancer with distant metastases, Breast cancer in postmenopausal women, Breast cancer hormone-dependent, Breast cancer with local metastases, Breast cancer with metastases, Breast cancer with regional metastases,Breast cancer with metastases, Common hormone-dependent forms of breast cancer, Common Breast Cancer, Recurrent Breast Cancer, Recurrence of breast tumors, Breast cancer, Estrogen-dependent breast cancer, Estrogen-Dependent Breast Cancer, Disseminated breast cancer with overexpression of HER2, Tumors of the mammary glands

Composition and form of release

Tablets, coated with a coating.

Tamoxifen (as citrate) 10 mg / 20 mg / 30 mg / 40 mg

In a planar cell pack of 10; In a box of 3 or 10 packages.

pharmachologic effect

Pharmacological action - antitumor, cytostatic, antiestrogenic.

Competitive (instead of the endogenous ligand) binds estrogen receptors in target organs by blocking formation estrogenretseptornogo complex.

Indications

Metastatic breast carcinoma, adjuvant therapy after surgical treatment of breast carcinoma.

Contraindications

Hypersensitivity.

pregnancy and lactation

Contraindicated in pregnancy (before treatment, pregnancy should be excluded). During treatment, reliable contraception should be provided.

Side effects

Pain in the bones and foci of tumor growth, nausea, vomiting, flushing, menstrual suppression in premenopausal, itching in the genital area, vaginal bleeding, swelling, anemia, ovarian cysts, phlebitis, thrombosis, blurred vision, skin rash.

Interaction

Mutual weakening of the effect with estrogens. When concomitant administration with drugs that lower blood clotting may potentiate anticoagulation (increased risk of bleeding).

Dosing and Administration

Inside. Usually prescribed 20-40 mg daily. With prolonged therapy, taking 30 mg daily is recommended.

Precautionary measures

It should be particularly careful with thrombocytopenia, leukopenia and hypercalcemia (mandatory control of blood calcium, and platelets).

storage Conditions

At a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Shelf-life

5 years.

Do not use after the expiry date printed on the package.